An Open-Label Pilot Phase 2 Study to Investigate Efficacy, Safety, and Intratumoral Kinetics of ALDOXORUBICIN in HIV-Infected Patients With Kaposi's Sarcoma

Trial Profile

An Open-Label Pilot Phase 2 Study to Investigate Efficacy, Safety, and Intratumoral Kinetics of ALDOXORUBICIN in HIV-Infected Patients With Kaposi's Sarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs Aldoxorubicin (Primary)
  • Indications Kaposi's sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CytRx Corporation
  • Most Recent Events

    • 18 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 17 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
    • 07 Jun 2016 Results assessing efficacy of Aldoxorubicin presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top